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In October 2014, the Food and Drug Administration (FDA) 
licensed the first serogroup B meningococcal (MenB) vaccine 
(MenB-FHbp [Trumenba, Wyeth Pharmaceuticals, Inc.]) as a 
3-dose series. In January 2015, FDA licensed a second MenB 
vaccine (MenB-4C [Bexsero, Novartis Vaccines]) as a 2-dose 
series. Both vaccines were approved for use in persons aged 
10–25 years. Following outbreaks of serogroup B meningo-
coccal disease on two college campuses in 2013, both MenB 
vaccines were granted Breakthrough Therapy designations, 
which expedites drug development and review by FDA, and 
were licensed based on accelerated approval regulations (1). On 
February 26, 2015, the Advisory Committee on Immunization 
Practices (ACIP) recommended use of MenB vaccines among 
certain groups of persons aged ≥10 years who are at increased 
risk for serogroup B meningococcal disease. This report sum-
marizes information on MenB administration and provides 
recommendations and guidance for use of these vaccines among 
persons aged ≥10 years in certain groups who are at increased 
risk for serogroup B meningococcal disease, and reviews the 
evidence considered by ACIP to make these recommendations. 
Recommendations for broader use of MenB vaccines in adoles-
cents and college students will be considered separately by ACIP.
Methods
The ACIP Meningococcal Vaccines Work Group reviewed 
safety and immunogenicity data from seven clinical trials of 
MenB-4C (2–7) (Novartis, unpublished data) and nine clinical 
trials of MenB-FHbp (8–13) (Pfizer, unpublished data) during its 
monthly teleconferences. The Work Group also evaluated pub-
lished peer-reviewed literature and unpublished data on menin-
gococcal disease epidemiology in the United States. A summary 
of the data reviewed and Work Group discussions was presented 
to ACIP, and recommendations for use of MenB vaccines among 
persons aged ≥10 years at increased risk for serogroup B meningo-
coccal disease were approved by ACIP at its February 26, 2015, 
meeting (meeting minutes are available at http://www.cdc.gov/
vaccines/acip/meetings/meetings-info.html).
The type and quality of evidence supporting the use of 
MenB vaccines in persons aged ≥10 years at increased risk for 
serogroup B meningococcal disease was evaluated using the 
Grading of Recommendations, Assessment, Development, 
and Evaluation (GRADE) framework (14), and determined 
to be type 2 (moderate level of evidence) for use in outbreak 
settings, and type 3 (low level of evidence) for use in persons 
at increased risk for serogroup B meningococcal disease. The 
recommendation was designated Category A (recommended 
for all persons in an age-based or risk-factor–based group) (15).
Persons at Increased Risk for Meningococcal 
Disease
Persons who have persistent deficiencies (e.g., genetic defi-
ciencies) in the complement pathway (e.g., C3, properdin, 
Factor D, Factor H, or C5-C9) have up to a 10,000-fold 
increased risk for meningococcal disease and can experience 
recurrent disease (16,17). Persons receiving eculizumab (Soliris, 
Alexion Pharmaceuticals) for treatment of atypical hemolytic 
uremic syndrome or paroxysmal nocturnal hemoglobinuria 
also are at increased risk because the drug binds to C5 and 
inhibits the terminal complement pathway (information avail-
able at http://soliris.net /sites/default/files/assets / soliris_pi.pdf ). 
Similarly, persons with functional or anatomic asplenia 
(including persons with sickle cell disease) appear to be at 
increased risk for meningococcal disease, and have a higher 
mortality rate (40%–70%) from the disease than healthy 
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populations (18). Among microbiologists who routinely work 
with Neisseria meningitidis isolates, the attack rate of laboratory-
acquired meningococcal infection has been estimated at 13 per 
100,000 persons, which is many fold higher than the rate for 
adults in the general population (19). In the United States, 
97%–98% of all cases of meningococcal disease are sporadic; 
however, outbreaks continue to occur. Recently, outbreaks of 
serogroup B meningococcal disease have been reported from 
several college campuses. Data from four college campus out-
breaks (March 2013–May 2015) showed a 200 to 1,400–fold 
increase in risk for meningococcal disease among students at 
these colleges during the outbreak period compared with the 
general population in this age group (Division of Bacterial 
Diseases, National Center for Immunization and Respiratory 
Diseases, CDC, unpublished data, 2015).
MenB Vaccine Immunogenicity and Safety
Because of the low incidence of serogroup B meningococcal 
disease, vaccine efficacy estimates were based on demonstration 
of immune response, as measured by serum bactericidal activ-
ity using human complement (hSBA), against a small number 
of serogroup B strains. In studies supporting U.S. licensure, 
immunogenicity was assessed by the proportion of subjects 
who achieved a ≥4-fold increase in hSBA titer for each of the 
strains tested, and the proportion of subjects who achieved a 
titer greater than or equal to the lower limit of quantification 
of the assay for all strains (composite response) (20,21). The 
lower limit of quantification was defined as the lowest amount 
of the antibody in a sample that can be reliably quantified.
MenB-4C Vaccine
MenB-4C consists of three recombinant proteins (Neisserial 
adhesin A [NadA], factor H binding protein [FHbp] fusion 
protein, and Neisserial Heparin Binding Antigen [NHBA] 
fusion protein), and outer membrane vesicles (OMVs) contain-
ing outer membrane protein PorA serosubtype P1.4. MenB-4C 
is licensed as a 2-dose series, with doses administered at least 
1 month apart, although in some studies, MenB-4C doses were 
administered up to 6 months apart.
In persons aged ≥10 years, safety and immunogenicity of 
MenB-4C were evaluated in seven clinical trials: six random-
ized controlled trials and one immunogenicity extension 
study (2–7) (Novartis, unpublished data). In one randomized 
controlled trial conducted in the United Kingdom, a subset 
of enrolled subjects (university students aged 18–24 years) 
received 2 doses of MenB-4C vaccine 1 month apart. One 
month following the second dose, 88% (95% confidence 
interval [CI] = 82%–93%) of subjects had a composite hSBA 
response to all three test strains; 66% (CI = 58%–72%) of the 
subjects had a composite hSBA response to all three test strains 
at 11 months after the second dose (20). In a randomized 
controlled trial conducted in Australia and Canada, persons 
aged 11–17 years received 2 doses of MenB-4C 1 month apart. 
One month following the second dose, 63% (CI = 57%–68%) 
of subjects had a composite hSBA response to all three test 
strains (20).
In an open-label study conducted in Germany and Italy, anti-
body responses to MenB-4C were assessed in laboratory work-
ers aged 18–50 years who were routinely exposed to Neisseria 
meningitidis. Among the subjects, 83% (CI  =  69%–92%) 
achieved an hSBA titer ≥1:8 against at least one of the three 
test strains 1 month after the second dose of MenB-4C (3).
In three clinical trials for which a control group was available, 
serious adverse events were assessed in 2,716 participants who 
received at least 1 dose of MenB-4C and for whom safety data 
were collected through 6 months postvaccination (2,4,6). Five 
serious adverse events were considered by the study investigator 
to be related (or possibly related) to the vaccine.* Rates of seri-
ous adverse events were similar in the vaccine and the control 
groups. In addition, information about serious adverse events 
was collected during three prelicensure vaccination campaigns 
in response to three outbreaks of serogroup B meningococcal 
disease (at two universities in the United States and in one 
region in Canada). A total of 59,091 participants in the vac-
cination campaigns received at least 1 dose of MenB-4C. Three 
serious adverse events were considered by the study investigator 
to be related (or possibly related) to the vaccine†; all resolved 
with no sequelae (CDC and Novartis, unpublished data). No 
deaths were considered to be related to MenB-4C in the clinical 
trials or campaigns. The most common solicited adverse reac-
tions observed in the 7 days after receipt of MenB-4C in the 
clinical trials were pain at the injection site, myalgia, erythema, 
fatigue, headache, induration, nausea, and arthralgia (9,20).
Safety and immunogenicity data regarding MenB-4C when 
co-administered with vaccines routinely administered to U.S. 
adolescents are not available.
MenB-FHbp Vaccine
MenB-FHbp consists of two purified recombinant FHbp 
antigens. One antigen from each FHbp subfamily (A and B) 
is included in the vaccine. MenB-FHbp is licensed as a 3-dose 
series, with the second and third doses administered 2 and 
6 months after the first dose.
* The administration of the investigational vaccine and a serious adverse event 
were considered reasonably related in time and the serious adverse event could 
not be explained by causes other than exposure to the investigational vaccine. 
The reported serious adverse events included tremor (one), dyspnea (one), 
acute thyroiditis (one), and juvenile arthritis (two).
† The reported serious adverse events included rhabdomyolysis (one), anaphylaxis 
(one) and fever (one).
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Safety and immunogenicity of MenB-FHbp in persons 
aged ≥10 years were evaluated in nine clinical trials: six ran-
domized controlled trials and three open label studies (8–13) 
(Pfizer, unpublished data). In a multicenter trial conducted in 
the United States, persons aged 11–17 years were randomly 
assigned to one of three groups. Group 1 received MenB-FHbp 
and quadrivalent human papillomavirus vaccine (4vHPV, 
[Gardasil Merck and Co.]), group 2 received MenB-FHbp and 
saline, and group 3 received 4vHPV and saline.
One  month  f o l l ow ing  th e  th i rd  do s e ,  81% 
(CI  =  78.0%–83.7%) of subjects in group 1 and 83.9% 
(CI = 81.1%–86.4%) of subjects in group 2 had a composite 
hSBA response to all four test strains (13,21). After the second 
of 3 doses, approximately 50% of the subjects in each study 
group had a composite hSBA response to all test strains. In 
studies conducted among European persons aged 11–18 years, 
the hSBA responses in subjects who received MenB-FHbp 
according to the same schedule were similar to hSBA antibody 
responses in subjects in the U.S. study (9,21).
In one open label study, immunogenicity was assessed among 
a small number of meningococcal laboratory workers who 
received the vaccine. Among the subjects, 50% achieved a titer 
greater than or equal to the lower limit of quantification to all 
four test strains (Pfizer, unpublished data).
Concomitant administration of MenB-FHbp with vaccines 
routinely administered to U.S. adolescents has been evaluated 
in three trials. Subjects received MenB-FHbp co-adminis-
tered with 4vHPV (Gardasil, Merck and Co.), MenACWY 
(Menactra, Sanofi Pasteur), Tdap (Adacel, Sanofi Pasteur) 
or dTaP/IPV (Repevax, Sanofi Pasteur) vaccines. Except for 
the antibody response to HPV type 18, no immunologic 
interference was observed for serogroup B or concomitant 
vaccine antigens (HPV types 6, 11, 16, MenACWY, tetanus, 
diphtheria, pertussis and IPV antigens) when MenB-FHbp 
was administered concomitantly (11,13) (Pfizer, unpublished 
data). For HPV type 18, noninferiority criteria (lower bound of 
the CI of the geometric mean titer ratio >0.67) were not met 
for the geometric mean titer ratio at 1 month after the third 
4vHPV vaccination (lower bound of the CI for the geometric 
mean titer ratio was 0.62); however, ≥99% of subjects achieved 
seroconversion for all four HPV antigens.
In four clinical trials (9,11–13) a total of 2,557 subjects 
received at least 1 dose of MenB-FHbp; four subjects reported 
seven serious adverse events that were considered by the study 
investigator to be related (or possibly related) to the vaccine.§ 
All vaccine-related serious adverse events resolved without 
sequelae. No increased risk for any specific serious adverse 
event considered to be clinically significant was identified in 
any of the studies. No deaths were considered to be related to 
MenB-FHbp. The most common solicited adverse reactions 
observed in the 7 days after receipt of MenB-FHbp in the 
clinical trials were pain at the injection site, fatigue, headache, 
myalgia, and chills (21).
Rationale for Recommendations
Certain groups of persons known to be at increased risk for 
meningococcal disease are recommended to be routinely vac-
cinated with a quadrivalent meningococcal conjugate vaccine 
(MenACWY), which protects against serogroups A, C, W, 
and Y (16). Many of these groups are also at increased risk for 
serogroup B meningococcal disease. Available immunogenicity 
and safety data support the use of MenB vaccines in groups at 
increased risk for serogroup B meningococcal disease.
Both MenB vaccines are approved for use in persons aged 
10–25 years; however, because there are no theoretical dif-
ferences in safety for persons aged >25 years compared with 
those aged 10–25 years, ACIP supported routine use of MenB 
vaccines in persons aged ≥10 years who are at increased risk for 
serogroup B meningococcal disease. These recommendations 
do not apply to children aged <10 years.
Recommendations
Certain persons aged ≥10 years who are at increased risk for 
meningococcal disease should receive MenB vaccine. These 
persons include:
•	 Persons with persistent complement component 
deficiencies.¶
•	 Persons with anatomic or functional asplenia.**
•	 Microbiologists routinely exposed to isolates of Neisseria 
meningitidis.
•	 Persons identified as at increased risk because of a 
serogroup B meningococcal disease outbreak.
Certain other groups are included in the MenACWY recom-
mendations for persons at increased risk, but are not included 
in this recommendation. MenB vaccines are not licensed for 
children aged <10 years and are not currently recommended 
for children aged 2 months–9 years who are at increased 
risk for serogroup B meningococcal disease. MenB vaccine 
is not recommended for persons who travel to or reside in 
countries where meningococcal disease is hyperendemic or 
epidemic because the risk for meningococcal disease in these 
countries generally is not caused by serogroup B. The vaccine 
is not currently recommended for routine use in first-year 
§ The reported serious adverse events included pyrexia (one), vomiting (one), vertigo 
(one), chills (one), headache (one), anaphylaxis (one) and neutropenia (one).
 ¶ Including inherited or chronic deficiencies in C3, C5-9, properdin, factor D, 
factor H, or who are taking eculizumab (Soliris).
 ** Including sickle cell disease.  
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college students living in residence halls, military recruits, or 
all adolescents. Recommendations for broader use of MenB 
vaccines in adolescents and college students will be considered 
separately by the ACIP.
MenB vaccine should be administered as either a 2-dose 
series of MenB-4C or a 3-dose series of MenB-FHbp. The 
same vaccine product should be used for all doses. Based on 
available data and expert opinion, MenB-4C or MenB-FHbp 
may be administered concomitantly with MenACWY vaccines, 
but at a different anatomic site, if feasible.
Precautions and Contraindications
Before administering MenB vaccines, providers should 
consult the package insert for precautions, warnings, and 
contraindications (20,21). Adverse events occurring after 
administration of any vaccine should be reported to the 
Vaccine Adverse Event Reporting System (VAERS). Reports 
can be submitted to VAERS online, by fax, or by mail. 
Additional information about VAERS is available by telephone 
(1–800–822–7967) or online (http://vaers.hhs.gov).
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